CAN-FITE BIOPHARMA LTD SPONSORE

Codice
canf
Risorse esterne
Opinione della community
Prezzo Variazione Volume
1.98 0 €
(0.00%)
34070
P/E Obiettivo ad 1anno
0 5 €

Compra - Vendi

0
Tutte le tue transazioni per questo titolo

Devi effettuare l'accesso


Grafico

Altri utenti che hanno investito

Transations in last week
Buy: 16
Sell : 7

edoardo Matteo Berci Simone Bonzanini LucaMazzu91 Federico Borghi

Commenti


Notizie

Form 6-K Can-Fite BioPharma Ltd. For: Jan 12 - StreetInsider.com

On January 12, 2017, Can-Fite BioPharma Ltd. (the “Company”) convened a Special Meeting of Shareholders, however, the meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company's Special ... Leggi

Can-Fite BioPharma (CANF) Reports $5M Registered Direct Offering - StreetInsider.com

Can-Fite BioPharma Ltd. (NYSE: CANF) today announced that it has entered into definitive agreements with institutional investors to receive gross proceeds of $5 million. In connection with the offering, the Company will issue 2,500,000 registered ... Leggi

Traders Checklist Stocks: Cigna Corporation (NYSE:CI) , Can-Fite Biopharma Ltd (NYSEMKT:CANF) - WsNews 4investors

Cigna Corporation (NYSE:CI) initiated the shares trading at $145.40 and showed negative change of -1.93% while the stock's final trade was registered at $ 141.97. However, its previous closing price was seen at $144.77. The stock negotiated total ... Leggi

Can-Fite BioPharma (CANF) Granted IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial - StreetInsider.com

Can-Fite BioPharma Ltd. (NYSE: CANF) received approval to commence patient enrollment in a Phase II study of its liver drug candidate Namodenoson (CF102) in the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic ...altro » Leggi

Can-Fite BioPharma (CANF) Receives First $500K Payment Related to CF10 Deal in South Korea - StreetInsider.com

Can-Fite BioPharma Ltd. (NYSE: CANF) received its first payment of $500,000 from Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS). Can-Fite recently announced entering a distribution agreement with CKD for the exclusive ...altro » Leggi

Can-Fite BioPharma (CANF) Enters Distribution Agreement for CF102 in South Korea - StreetInsider.com

Can-Fite BioPharma Ltd. (NYSE: CANF) announced it has signed a distribution agreement with Chong Kun Dang Pharmaceuticals (CKD) for the exclusive right to distribute CF102 for the treatment of liver cancer in South Korea, upon receipt of regulatory ...altro » Leggi

Can-Fite BioPharma's (CANF) Phase II CF101 Study Failed to Meet Primary Endpoint in Glaucoma - StreetInsider.com

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced that its subsidiary, ...altro » Leggi

Demandware Inc (DWRE), Galena Biopharma Inc (GALE), Can Fite Biopharma Ltd (ADR) (CANF), Michael Kors ... - TCC

Demandware Inc. (NYSE:DWRE), Galena Bio Pharma Inc. (NASDAQ:GALE), Can Fite Biopharma Ltd (NYSEMKT:CANF), and Michael Kors Holdings Ltd (NYSE:KORS) are among the top gainers through pre-market trade today. The Country Caller takes a ...altro » Leggi

Can-Fite Biopharma Ltd. ADR - MarketWatch

Can-Fite Biopharma Ltd. ADR. NYSE MKT: CANF. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders. /marketstate/country/us. Can ... Leggi

Psoriasis Market Global Analysis and Pipeline Landscape Assessment for H2 2016 - MarketWatch

Company Analysis and Positioning discussed in this research are AbbVie Inc, Abeome Corporation, AbGenomics International, Inc., Addex Therapeutics Ltd, Advinus Therapeutics Ltd, Affibody AB, Albireo AB, Almirall, S.A., Alteogen Inc., Amgen Inc., Anacor ...altro » Leggi